Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29880757 | 1.00 | NR1H4 (0.84) | NR1H4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3575445 | 1.00 | NR1H4 (0.84) | NR1H4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29881439 | 1.00 | NR1H4 (0.84) | NR1H4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3562531 | 1.00 | NR1H4 (0.84) | NR1H4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3562242 | 0.99 | NR1H4 (0.82) | NR1H4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29880641 | 0.99 | NR1H4 (0.82) | NR1H4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3568883 | 0.99 | NR1H4 (0.82) | NR1H4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29880683 | 0.99 | NR1H4 (0.82) | NR1H4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3562115 | 0.93 | NR1H4 (0.81) | NR1H4KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3571268 | 0.93 | NR1H4 (0.81) | NR1H4KCNH2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645785-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | claimed |
| US-20080021027-A1 | Novel benzimidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | US | claimed |
| US-7645785-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080021027-A1 | Novel benzimidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021027-A1 | Novel benzimidazole derivatives | NR1H4, GPR119, GLP1R | NR1H4 1/4885KCNH2 3647/4885CYP3A4 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.